Anti-CGRP monoclonal antibodies are the first migraine-specific preventive treatments, reducing monthly migraine days with minimal side effects — even in patients who failed other preventives.
First target-specific migraine prophylaxisAnti-CGRP monoclonal antibodies are the first preventive migraine treatments designed specifically to target migraine biology, unlike all prior preventives which were repurposed from other therapeutic areas.
What the researchers found
Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) reduced monthly migraine days in both chronic and episodic migraine with minimal clinically significant adverse events. Evidence also supports efficacy in refractory migraine patients despite optimal existing prophylaxis. This is the first target-specific migraine prophylaxis drug class — previous preventives were all repurposed from other indications and had poor side effect profiles.
Why it matters
Migraine affects hundreds of millions of people globally, yet prior preventive treatments were never designed for migraine and commonly cause side effects that lead patients to stop taking them. Anti-CGRP monoclonal antibodies represent a paradigm shift: the first drugs engineered specifically to target migraine biology, with efficacy demonstrated even in patients who failed other preventive treatments.
How the study worked
Structured literature review of PubMed (January 2009 to November 2019) using search terms for migraine, CGRP, erenumab, fremanezumab, and galcanezumab. Included human clinical trials and studies in English reporting pharmacology, efficacy, and adverse events. Excluded initial pharmacokinetic and preclinical studies.
Who was studied
Patients with chronic and episodic migraine, including those with refractory migraine despite existing prophylaxis
What this study cannot tell us
The literature search ended in November 2019, so longer-term real-world effectiveness and safety data accumulating after that point are not included. The review does not include eptinezumab (the fourth anti-CGRP mAb, approved in 2020). Specific numerical outcomes (effect sizes, responder rates) are not reported in the abstract. The high cost of CGRP antagonists is acknowledged as a barrier but not quantified.
How to read the evidence
This is a structured literature review synthesizing pivotal clinical trial data (phase 2 and 3) for three anti-CGRP monoclonal antibodies. The underlying evidence includes large randomized controlled trials, though the review itself is a secondary synthesis rather than a systematic review with meta-analysis.
When this study was published
Published in 2020 with a literature search through November 2019. Since then, a fourth anti-CGRP mAb (eptinezumab) was approved, oral CGRP antagonists have expanded the class, and substantial real-world data has accumulated. The core efficacy and safety conclusions remain accurate.
The bigger picture
The anti-CGRP monoclonal antibodies mark the beginning of precision medicine for migraine — drugs designed from the ground up based on understanding of migraine pathophysiology rather than serendipitous discovery. This shift has implications beyond migraine, demonstrating that targeting specific peptide pathways can produce therapies that are both more effective and better tolerated than non-specific alternatives. The success of this drug class has also spurred development of oral CGRP antagonists (gepants) and further exploration of other neuropeptide targets.
Questions still open
- How do anti-CGRP monoclonal antibodies compare to each other in head-to-head clinical trials?
- What are the long-term safety and efficacy outcomes beyond the initial clinical trial periods?
- Will newer oral CGRP antagonists (gepants) eventually replace injectable monoclonal antibodies for most patients?
Common questions
How are anti-CGRP antibodies different from other migraine preventives?
Can these drugs help if other migraine preventives haven't worked for me?
Read the original research
Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
The Annals of pharmacotherapy, 54(8), 795-803
Citation
Arca, Karissa; Reynolds, Jenna; Sands, Kara A; Shiue, Harn J. (2020). Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.. The Annals of pharmacotherapy, 54(8), 795-803. https://doi.org/10.1177/1060028020903417